AT-56

• Description :

  AT-56 is a potent, selective and orally active inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS), with an IC50 of 95 μM and Ki of 75 μM. AT-56 could selectively suppress the drowsiness or pain reaction mediated by L-PGDS-catalyzed PGD2[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H228, H315, H319

• Target :

  PGE synthase

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/at-56.html

• Purity :

  99.75

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  N1(CCCCC2=NNN=N2)CC/C(CC1)=C3C4=CC=CC=C4C=CC5=CC=CC=C/35

• Molecular Formula :

  C25H27N5

• Molecular Weight :

  397.52

• Precautions :

  H228, H315, H319

• References & Citations :

  [1]Irikura D, et, al. Biochemical, functional, and pharmacological characterization of AT-56, an orally active and selective inhibitor of lipocalin-type prostaglandin D synthase. J Biol Chem. 2009 Mar 20; 284 (12) : 7623-30.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [162640-98-4]